Leadership & Pay ·
Cadrenal Therapeutics, Inc. appointed John P. Sharp as Interim Chief Financial Officer effective June 25, 2026…
CVKDCadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. appointed John P. Sharp as Interim Chief Financial Officer effective June 25, 2026, replacing Quang X. Pham. The company is searching for a permanent CFO. Additionally, Steven Zelenkofske resigned from the Board of Directors effective June 30, 2026. Following this, the Board realigned its members into three classes, which included the movement of Dr. Glynn Wilson from Class I to Class III. Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic solutions for patients with serious and life-threatening conditions.